

Table S3. B) Clinical data for the patients included from the IA13 CoMMpass study. FISHseq; Canonical Translocations identified by long-insert Whole Genome Sequencing. S:Sample, nd: not detected. NA: no data. Survival data was updated using the IA16 CoMMpass version.

Patient_ID	Patient Age	Sex	Ig class	light chain	FISHseq	ONV	ISS	R-ISS	IMiD received S1-2	PI received S1-2	HDM received S1-2	Intervening treatment* S1-S2	Best response S1-S2	Interval S1-S2 (months)	Treatment S2-S3	Best response	Interval S2-S3	Treatment S3	Response	Interval S3-S4	Treatment S4	Response	PFS, months	death occurred (y=1)	OS/Last follow-up (months)	
40	69	Female	Unknown	Kappa	t(11;14)		1		x		x	VCD/VRCd/VCD/HDM/R/RD	VGPR	21	Carfilz/Carfilz/CarfD	VGPR		12	PomDara	VGPR	21	SeId	VGPR	18	0	72
41	80	Male	IgA	Kappa	t(4;14)	del13q	2		x		x	VRD/VRCd/Carf/VRD/CarfT	VGPR	36	Dara	SD							18	1	65	
42	75	Male	IgG	Kappa	nd	del13q	1				x	VCD/V	VGPR	30	VRD	VGPR							26	1	67	
43	55	Male	IgG	Lambda	t(4;14)	del13q	1	2	x		x	VRD/HDM/HDM	VGPR	30	CarfRD/PomD/RPembD	PR		21	DikalDA	SD				29	1	72
44	64	Male	IgG	Kappa	t(11;14)		1	1	x		x	VRD/HDM/R/VenD	VGPR	45	Dara	PR							5	0	71	
45	39	Female	Unknown	Kappa	t(11;14)		1	1			x	VRD/HDM/R/VenD	sCR	36	CarfRD	VGPR							37	0	43	
46	74	Male	Unknown	Kappa	na		3	2	x		x	VCD/VD/VCD/VRD	PR	18		NA							7	1	21	
47	82	Female	Unknown	Lambda	t(4;14)		3	3	x		x	VD/R/RD/R	VGPR	21	R	VGPR							19	1	52	
48	67	Female	Unknown	Kappa	nd	del13q	3	2	x		x	VD/R	VGPR	18	Pom	NA							17	1	23	
49	70	Female	IgA	Lambda	nd		3	2	x		x	HDM/VRD/VCD	VGPR	18		NA							10	1	17	
50	68	Male	IgG	Kappa	t(11;14)		1		x		x	VCD/R/CarfD/CarfPomD	PR	36	CarfPomD/Carf	SD							2	0	65	
51	75	Male	IgG	Kappa	nd	del13q	3	2	x		x	VRD/VRCd/Carf/Pom	PR	18		NA							9	1	19	
52	45	Female	IgG	Lambda	nd		3	2	x		x	VCD/VRCd/HDM/RD	CR	39	Dara/CarfPomD	PR							36	0	66	
53	75	Female	IgG	Lambda	nd		3	2			x	CarfMPD	sCR	42		NA							42	0	67	
54	68	Female			t(6;14)	del13q	1	2	x		x	HDM/T	CR	33		NA							32	0	45	
55	72	Female			nd		3	2			x	VMP	VGPR	18	RD	VGPR							17	0	59	
56	53	Female	IgG	Kappa	t(11;14)		3	2	x		x	HDM	PR	15	RPanod	PR							15	0	51	
57	57	Male	IgG	Lambda	t(12;14)		3	2	x		x	HDM	sCR	27	CarfPomD	VGPR							26	0	63	
58	66	Female			nd	del13q	3	2			x	VMP	VGPR	9	RD	PD							8	1	15	
59	67	Female	IgA	Lambda	t(4;14)	del13q	2	2	x		x	VRD	VGPR	18	IxaRD	VGPR							11	0	62	
60	70	Male	IgG	Kappa	t(14;20)		2		x		x	VRD/RD	PR	21		NA							11	1	19	
61	75	Male	Unknown	Kappa	t(11;14)	del17p	2	2			x	VMP	VGPR	15	RD	SD							15	1	36	
62	66	Male	IgG	Kappa	t(4;14)	del13q	3	3	x		x	VCD/VD/RD	VGPR	27	RD	PD							21	1	33	
63	67	Male	Unknown	Kappa	t(8;14)		1	2	x		x	HDM	PD	15	CarfRD	PD							3	1	18	
64	64	Male			t(4;14)	del13q	3	3	x		x	VTD	PD	3	VCD	SD							3	1	13	
65	55	Female	IgA	Lambda	nd		3		x		x	VD/VRD	VGPR	24	VD	NA							19	1	22	
66	66	Male	Unknown	Kappa	nd	del13q	2	2	x		x	VRD/CarfD	PR	21		NA							7	1	40	
67	70	Female			nd	del13q	2	2			x	VMP	VGPR	18	RD	PR							19	0	50	

*Treatment:
C: cyclophosphamide
D: dexamethasone
P: prednisone
V: velcade/bortezomib
R: revlimid/lenalidomide
T: thalidomide
Pom: pomalidomide
HDM: high dose melphalan (ASCT)
Carf: carfilzomib
Pano: panobinostat
Pemb: pembrolizumab
Sei: selinexor
IDa: IDASAN UTLIN-D
Ven: venetoclax
Dara: daratumumab